10 Takeover Targets to Watch This Fall
Pace of Biopharma M&A Slows from First Half Stampede of Deals
Marijuana Use in Adults Living with Sickle Cell Disease
Most States Do Not Specify Sickle Cell Disease as a Qualifying Condition for Legal Access to Marijuana
Bioprocessing Companies Push Limits of Upstream Technologies
Goal Is to Maximize Efficiency in Bioprocess Operations
Bispecific Playgrounds? No, Factory Floors
Developers Prepare for Future Biologics Work by Exploring a Multitude of Antibody Formats
For full access to this article login to GEN Select now.
Advertorial: Accelerating Therapeutic Development and Manufacturing
Using a Single High-Performance Delivery Platform for Cell Engineering
- Identify more relevant and efficacious candidates faster, more cost-effectively, and with reduced risk. These goals are common to researchers developing therapeutics of all modalities, whether small molecules, proteins and antibodies, or cell-based medicines. Flexible, efficient cell engineering is central to attaining these goals. MaxCyte’s delivery platform accelerates the discovery/development, ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.